They are for type 2 diabetes and weight loss in people who make insulin
Research on maintenance dosing is limited, but Stegen et al
Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
Weekly Formulations GLP-1 medications come in both daily and weekly formulations, offering flexibility to suit different preferences and lifestyles
De fleste brukere oppnr nsket fargeniv innen uke 34
There are two primary classes of GST prodrugs